First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying liver function that is clinically evaluated by the...

Full description

Bibliographic Details
Main Authors: Sri Harsha Tella, Anuhya Kommalapati, Amit Mahipal, Zhaohui Jin
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Biomedicines
Subjects:
liver cancer
immunotherapy
atezolizumab
bevacizumab
nivolumab
Online Access:https://www.mdpi.com/2227-9059/10/6/1304

Similar Items

Similar Items